Targeted cancer therapy: the initial high concentration may slow down the selection for resistance

TL;DR

This paper suggests that starting cancer treatment with high drug doses could delay resistance development.

Contribution

The novelty is proposing high initial drug concentrations as a strategy to reduce resistance in targeted cancer therapy.

Findings

Starting with low drug levels selects for drug resistance.

Maximizing initial drug levels may slow resistance development.

Preemptive combination therapies could be more effective.

Abstract

Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance. One should propose that initial drug levels must be maximized, and durations may be minimized, ideally, as portions of preemptive combination of targeted drugs.

Figures